80 related articles for article (PubMed ID: 19043920)
1. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
Antivir Ther; 2008; 13(7):863-73. PubMed ID: 19043920
[TBL] [Abstract][Full Text] [Related]
2. Brincidofovir: A Novel Agent for the Treatment of Smallpox.
Huston J; Curtis S; Egelund EF
Ann Pharmacother; 2023 Oct; 57(10):1198-1206. PubMed ID: 36688308
[TBL] [Abstract][Full Text] [Related]
3. Development of CMX001 for the Treatment of Poxvirus Infections.
Lanier R; Trost L; Tippin T; Lampert B; Robertson A; Foster S; Rose M; Painter W; O'Mahony R; Almond M; Painter G
Viruses; 2010 Dec; 2(12):2740-2762. PubMed ID: 21499452
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive literature review of monkeypox.
Hatmal MM; Al-Hatamleh MAI; Olaimat AN; Ahmad S; Hasan H; Ahmad Suhaimi NA; Albakri KA; Abedalbaset Alzyoud A; Kadir R; Mohamud R
Emerg Microbes Infect; 2022 Dec; 11(1):2600-2631. PubMed ID: 36263798
[TBL] [Abstract][Full Text] [Related]
5. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
[TBL] [Abstract][Full Text] [Related]
6. The Role of Brincidofovir in Preparation for a Potential Smallpox Outbreak.
Foster SA; Parker S; Lanier R
Viruses; 2017 Oct; 9(11):. PubMed ID: 29773767
[TBL] [Abstract][Full Text] [Related]
7. [
Dyall J; Johnson RF; Chefer S; Leyson C; Thomasson D; Seidel J; Ragland DR; Byrum R; Jett C; Cann JA; St Claire M; Jagoda E; Reba RC; Hammoud D; Blaney JE; Jahrling PB
J Virol; 2017 Nov; 91(21):. PubMed ID: 28814515
[TBL] [Abstract][Full Text] [Related]
8. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
9. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
10. Orthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.
Smee DF
Future Virol; 2013 Sep; 8(9):891-901. PubMed ID: 24563659
[TBL] [Abstract][Full Text] [Related]
11. Poxvirus antigen staining of immune cells as a biomarker to predict disease outcome in monkeypox and cowpox virus infection in non-human primates.
Song H; Janosko K; Johnson RF; Qin J; Josleyn N; Jett C; Byrum R; St Claire M; Dyall J; Blaney JE; Jennings G; Jahrling PB
PLoS One; 2013; 8(4):e60533. PubMed ID: 23577120
[TBL] [Abstract][Full Text] [Related]
12. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
[TBL] [Abstract][Full Text] [Related]
13. Highlights in antiviral drug research: antivirals at the horizon.
De Clercq E
Med Res Rev; 2013 Nov; 33(6):1215-48. PubMed ID: 22553111
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
15. Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver.
Xu RH; Rubio D; Roscoe F; Krouse TE; Truckenmiller ME; Norbury CC; Hudson PN; Damon IK; Alcamà A; Sigal LJ
PLoS Pathog; 2012 Jan; 8(1):e1002475. PubMed ID: 22241999
[TBL] [Abstract][Full Text] [Related]
16. Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics.
Parker S; Siddiqui AM; Painter G; Schriewer J; Buller RM
Viruses; 2010 Sep; 2(9):1918-1932. PubMed ID: 21994714
[TBL] [Abstract][Full Text] [Related]
17. The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus.
Denzler KL; Schriewer J; Parker S; Werner C; Hartzler H; Hembrador E; Huynh T; Holechek S; Buller RM; Jacobs BL
Vaccine; 2011 Dec; 29(52):9691-6. PubMed ID: 21983358
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
